Skip to content
Research Article in European Journal of Cancer journal 2022 – Tumor burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy
Home/Publications & abstracts/Research Article in European Journal of Cancer journal 2022 – Tumor burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy
Research Article in European Journal of Cancer journal 2022 – Tumor burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy
webmaster@ervaccinetechnologies.com2022-06-16T07:59:13+00:00
Share on your favorite plateform
Page load link